Wednesday, 1 September 2010
Teriflunomide significantly reduced annualized relapse rate and was well tolerated in MS patients
First results from the TEMSO phase III trial to be presented during the ECTRIMS congress in October 2010.
Sanofi-aventis announced today that the investigational once-daily oral drug teriflunomide significantly reduced annualized relapse rate (ARR) at 2 years versus placebo in patients with relapsing multiple sclerosis (RMS), thus achieving the primary endpoint in the TEMSO phase III trial. Both the 7mg and 14mg doses of teriflunomide were well tolerated with a similar number of patients reporting either treatment-emergent adverse events (TEAEs) or TEAEs leading to treatment discontinuation in the treatment arms versus placebo. For more click here